Dr. Allison Lipitz-Snyderman is a health services researcher focused on quality assessment and improvement in cancer care. Her research falls into three general areas: assessment of variation in practice and outcomes, examination of harm due to medical care, and evaluation of quality improvement activities. Dr. Lipitz-Snyderman received funding from the National Institute for Health Care Management (NIHCM) Foundation to assess the extent of physician-driven variation in the use of services that tend to be overused. She is currently building on this work to examine hospital-level variation in outcomes of cancer care. Dr. Lipitz-Snyderman has worked to assess the burden of potentially preventable harm that occurs during cancer treatment in both inpatient and outpatient settings. She examined the issue of infections associated with using long-term central venous catheters to administer intravenous medications such as chemotherapy. She also led a study to identify adverse events across 1 year of cancer treatment using medical record reviews, funded by the United Hospital Fund. Through this work, Dr. Lipitz-Snyderman and her colleagues developed and tested an oncology-specific screening tool to guide the detection of adverse events from medical record reviews. Dr. Lipitz-Snyderman also led an evaluation of a multifaceted intervention, the Michigan Keystone ICU Project, aimed to reduce device-related bloodstream infections across the state of Michigan. Using population-based Medicare claims, she demonstrated that the initiative’s implementation was associated with reductions in mortality. Dr. Lipitz-Snyderman is a member of the MSK Center for Health Policy and Outcomes and is Co-chair of the MSK Cancer Alliance Quality, Value, and Outcomes Committee.